Melissa Johnson named program director of lung cancer research at Sarah Cannon

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

Melissa Johnson was named program director of lung cancer research at Sarah Cannon.

In this role, Johnson will lead the lung cancer clinical trial portfolio across the Sarah Cannon network.

Since joining Sarah Cannon in 2014, Johnson has served as the associate director of lung cancer research at Sarah Cannon Research Institute, supporting the growth of early phase compounds in thoracic malignancies.

Johnson will continue to work in early phase drug development as well as lead the Solid Tumor Immune Effector Cellular Therapy Program at Sarah Cannon. She is also the chair of the Cancer Committee at TriStar Centennial Medical Center in Nashville.

Johnson begins her position in January at Sarah Cannon headquarters in Nashville. She will continue to care for patients as a partner with Tennessee Oncology, PLLC.

Table of Contents

YOU MAY BE INTERESTED IN

Acting Director Dr. Krzysztof Ptak’s words reverberated throughout the meeting room—and the heads of several of us—during the National Cancer Institute’s Office of Cancer Centers update on the final day of the 2024 Association of American Cancer Institutes/Cancer Center Administrators Forum Annual Meeting in Chicago.
“Bridge to Bahia” exhibit.Source: Sylvester Comprehensive Cancer CenterKaren Estrada, a survivor of acute myeloid leukemia, used visual art to communicate with her two boys while undergoing a bone marrow transplant at Sylvester Comprehensive Cancer Center. Because Estrada’s treatment required isolation, and her young children could not yet read and write, she sought out other creative vessels to foster closeness between them.

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login